---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-25-001958"
form_type: "8-K"
ticker: "BGLC"
cik: "0001737523"
company_name: "BioNexus Gene Lab Corp"
filed_at: "2025-03-25T23:59:59+00:00"
generated_at: "2026-05-24T05:53:26.604676+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# BioNexus Gene Lab shareholders approve reverse stock split at 1:5 to 1:10 ratio

## Summary
- 98.36% of votes cast (4.94B) approved reverse stock split; ratio range of 1:5 to 1:10 at Board discretion.
- Series Z Preferred Stock with 5B votes mirrored common stock votes exclusively for this proposal.
- Adjournment proposal also passed with 98.60% approval.
- Special Meeting held March 19, 2025; no other matters voted.

## SEC filing metadata
- accession: 0001477932-25-001958
- form_type: 8-K
- ticker: BGLC
- cik: 0001737523
- company_name: BioNexus Gene Lab Corp
- filed_at: 2025-03-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737523/000147793225001958/0001477932-25-001958-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737523/000147793225001958/bglc_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-25-001958
- JSON: https://secwatch.observer/filing/0001477932-25-001958.json
- Plain text: https://secwatch.observer/filing/0001477932-25-001958.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.